NIM Norwood Imm.

RNS Number:6676I
Norwood Immunology Ld
08 September 2006


FOR IMMEDIATE RELEASE                                         8 September 2006


                           NORWOOD IMMUNOLOGY LIMITED
                    ('Norwood Immunology' or 'the Company')


                     Appointments to the Board of Directors



Norwood Immunology Limited (AIM: NIM), the company focussed on the rejuvenation
of the immune system, today announces two appointments to the Board of Directors
with immediate effect.

The appointment of both Mr Brian Guzman and Mr Henry Stein are following the
recently announced changes to the composition of the Company's shareholder base
and the provision of a A$1 million working capital facility by Indus Opportunity
Master Fund, Ltd.

Mr Brian Flaviano Guzman (aged 35) is joining the Board as a non-executive director.  
Brian Guzman joined Indus Capital Partners in August 2005 as a Managing Director 
and Counsel.  Mr. Guzman specialized in the formation and structuring of private 
investment funds (both domestic and offshore), private equity funds and registered 
investment companies, and representation of registered and unregistered investment 
advisors.  He is currently on the board of Indus India Infrastructure SPV Ltd and 
ISFF Bestford SPV Ltd.

Mr Henry Wallach Stein (aged 48) is also joining the Board as a non-executive
director. Mr Stein is a Managing Director of Indus Capital Advisors (HK) Ltd,
and has acted as an observer of several boards.  Most recently, Mr Stein was
formerly a Director of Green Cartridge Company Limited, an international company
incorporated under the laws of the British Virgin Islands and resigned as a
director in December 2005.

There are no other matters which are required to be announced as required under
paragraph (g) of Schedule 2 of the AIM Rules in respect of either director.

Richard Williams, CEO of Norwood Immunology, commented: "On behalf of the Board
I would like to extend a warm welcome to both Brian Guzman and Henry Stein and
look forward to their contribution."


For further information please contact:

Richard Williams, Chief Executive Officer, Norwood Immunology Limited
+44 (0)7860 295153


Lisa Baderoon, Mark Court, Mary-Jane Johnson, Buchanan Communications
+44 (0)207 466 5000


Notes for editors:

Norwood Immunology has licensed its immunology intellectual property to TAP
Pharmaceutical Products Inc. for commercialization in the United States,
utilizing TAP's GnRH analogue, Lupron Depot(R) (leuprolide acetate for depot
suspension). This combined initiative is exploring the use of Lupron Depot in
regenerating the thymus gland and in turn "re-booting" the body's immune system,
enabling patients to better recover from life-threatening diseases.

TAP Pharmaceutical Products Inc., located in Lake Forest, IL., U.S.A., is a
joint venture between Abbott, headquartered in Abbott Park, IL., U.S.A ., and
Takeda Pharmaceutical Company Limited of Osaka, Japan. TAP currently markets
Lupron Depot and Prevacid(R) (lansoprazole). For more information about TAP and
its products, please visit the company's web site at www.tap.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOABRGDCSSGGGLR

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Giu 2023 a Giu 2024